Company intelligence / Profile preview

Immunai

New York, NY, United Statesimmunai.com ↗

Ownership: Private
Employees: ~200
Development stage: Preclinical

Overview

Immunai is developing an AI platform that maps the immune system at single-cell resolution to facilitate drug discovery and development. The company has not yet reported clinical trial results.

Therapeutic areas: Immunology
Modalities: Immunomodulatory drugs
Industry: Drug Discovery Services

Partnerships

Partnerships with pharmaceutical companies and academic institutions including Harvard, Stanford, Memorial Sloan Kettering, and Baylor College of Medicine

Beyond the preview

Go deeper on Immunai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunai.